Dataset Information

BHA-CS: A novel cognitive composite for Alzheimer's disease and related disorders.

ABSTRACT:

Introduction

Composite scores based on psychometrically rigorous cognitive assessments are well suited for early diagnosis and disease monitoring.

Methods

We developed and cross-validated the Brain Health Assessment-Cognitive Score (BHA-CS), based on a brief computerized battery, in 451 cognitively normal (CN) and 399 cognitively impaired (mild cognitive impairment [MCI] or dementia) older adults. We investigated its long-term reliability and reliable change indices at longitudinal follow-up (N = 340), and the association with amyloid beta (A?) burden in the CN subgroup with A? positron emission tomography (N = 119).

Results

The BHA-CS was accurate at detecting cognitive impairment and exhibited excellent long-term stability. Reliable decline over one year was detected in 75% of participants with dementia, 44% with MCI, and 3% of CN. Among CN, the A?-positive group showed worse longitudinal performance on the BHA-CS compared to the A?-negative group.

Discussion

The BHA-CS is sensitive to cognitive decline in preclinical and prodromal neurodegenerative disease.

SUBMITTER: Tsoy E

PROVIDER: S-EPMC7306517 | biostudies-literature | 2020

REPOSITORIES: biostudies-literature

ACCESS DATA

Publications

BHA-CS: A novel cognitive composite for Alzheimer's disease and related disorders.

Tsoy Elena E Erlhoff Sabrina J SJ Goode Collette A CA Dorsman Karen A KA Kanjanapong Suchanan S Lindbergh Cutter A CA La Joie Renaud R Strom Amelia A Rabinovici Gil D GD Lanata Serggio C SC Miller Bruce L BL Tomaszewski Farias Sarah E SE Kramer Joel H JH Rankin Katherine P KP Possin Katherine L KL

Alzheimer's & dementia (Amsterdam, Netherlands) 20200621 1

<h4>Introduction</h4>Composite scores based on psychometrically rigorous cognitive assessments are well suited for early diagnosis and disease monitoring.<h4>Methods</h4>We developed and cross-validated the Brain Health Assessment-Cognitive Score (BHA-CS), based on a brief computerized battery, in 451 cognitively normal (CN) and 399 cognitively impaired (mild cognitive impairment [MCI] or dementia) older adults. We investigated its long-term reliability and reliable change indices at longitudina ...[more]

PMID: 32582835

Similar Datasets

Project description:BACKGROUND:There is growing interest in identifying sensitive composite cognitive tests to serve as primary endpoints in preclinical Alzheimer's disease (AD) treatment trials. We reported previously a composite cognitive test score sensitive to tracking preclinical AD decline up to 5?years prior to clinical diagnosis. Here we expand upon and refine this work, empirically deriving a composite cognitive test score sensitive to tracking preclinical AD decline up to 11?years prior to diagnosis and suitable for use as a primary endpoint in a preclinical AD trial. METHODS:This study used a longitudinal approach to maximize sensitivity to tracking progressive cognitive decline in people who progressed to the clinical stages of AD (n =?868) compared to those who remained cognitively unimpaired during the same time period (n =?989), thereby correcting for normal aging and practice effects. Specifically, we developed the Alzheimer's Prevention Initiative Preclinical Composite Cognitive test (APCC) to measure very early longitudinal cognitive decline in older adults with preclinical AD. Data from three cohorts from Rush University were analyzed using a partial least squares (PLS) regression model to identify optimal composites within different time periods prior to diagnosis, up to 11?years prior to diagnosis. The mean-to-standard deviation ratio (MSDRs) is an indicator of sensitivity to change and was used to inform the final calculation of the composite score. RESULTS:The optimal composite, the APCC, is calculated: 0.26*Symbol Digit Modalities +?2.24*MMSE Orientation to Time?+?2.14*MMSE Orientation to Place +?0.53*Logical Memory Delayed Recall +?1.36* Word List-Delayed Recall +?0.68*Judgment of Line Orientation +?1.39*Raven's Progressive Matrices Matrices (subset of 9 items from A and B). The MSDR of the APCC in a population of preclinical AD individuals who eventually progress to cognitive impairment, compared to those who remained cognitively unimpaired during the same time period, was -?1.10 over 1 year. CONCLUSIONS:The APCC is an empirically derived composite cognitive test score with high face validity that is sensitive to preclinical AD decline up to 11?years prior to diagnosis of the clinical stages of AD. The components of the APCC are supported by theoretical understanding of cognitive decline that occurs during preclinical AD. The APCC was used as a primary outcome in the API Generation Program trials.

Dataset Information

BHA-CS: A novel cognitive composite for Alzheimer's disease and related disorders.

Introduction

Methods

Results

Discussion

Publications

BHA-CS: A novel cognitive composite for Alzheimer's disease and related disorders.

Similar Datasets

OmicsDI is part of the ELIXIR infrastructure

Tweets